Related Experiment Videos
CHEK2 variants associate with hereditary prostate cancer
E H Seppälä1, T Ikonen, N Mononen
1Laboratory of Cancer Genetics, Institute of Medical Technology, Lenkkeilijänkatu 8,University of Tampere and Tampere University Hospital, FIN-33014 University of Tampere, Finland.
British Journal of Cancer
|November 13, 2003
Summary
Genetic variants in the CHEK2 gene are linked to hereditary prostate cancer (HPC). This study found specific CHEK2 mutations, 1100delC and I157T, were more common in Finnish HPC patients, suggesting a role in familial prostate cancer risk.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- CHEK2 gene variants have been associated with sporadic prostate cancer.
- Understanding genetic predispositions for hereditary prostate cancer (HPC) is crucial for risk assessment and prevention.
Purpose of the Study:
- To investigate the association of specific CHEK2 variants (1100delC and I157T) with hereditary prostate cancer in a Finnish cohort.
- To determine if these CHEK2 variants contribute to the familial clustering of prostate cancer.
Main Methods:
- Case-control study comparing allele frequencies in 120 HPC patients and 480 population controls from Finland.
- Genotyping for the CHEK2 1100delC and I157T variants.
- Segregation analysis within families with a history of prostate cancer.
Main Results:
- The truncating CHEK2 variant 1100delC was significantly elevated in HPC patients (3.3%) compared to controls (OR=8.24, P=0.02).
- Suggestive evidence of segregation of the 1100delC mutation with prostate cancer was observed in affected families.
- The CHEK2 I157T variant was also more frequent in HPC patients (10.8%) than in controls (OR=2.12, P=0.04).
Conclusions:
- CHEK2 variants, including 1100delC and I157T, appear to be low-penetrance alleles predisposing to prostate cancer.
- These variants may contribute to the familial aggregation of prostate cancer within the population.